COMPLEMENT INHIBITORS AND USES THEREOF
0 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody, which bound to C2a and blocked its ability to activate complement was generated and designated 175-62. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number PTA-1553.
-
Citations
17 Claims
-
1. (canceled)
- 2. An inhibitor molecule that binds to C2a or the C2a portion of C2 and inhibits both the classical and the lectin complement pathways.
-
3. An inhibitor molecule that binds to the same epitope as the monoclonal antibody 175-62.
-
8-9. -9. (canceled)
-
11-14. -14. (canceled)
-
17-18. -18. (canceled)
Specification